Results 281 to 290 of about 1,436,444 (347)
Some of the next articles are maybe not open access.
Retargeting CD19 CAR T cells via engineered CD19-fusion proteins.
Molecular Pharmaceutics, 2019CD19-targeted chimeric antigen receptor (CAR) T-cells (CAR19s) show remarkable efficacy in the treatment of relapsed/refractory acute lymphocytic leukemia and Non-Hodgkin lymphoma.
Justin R. Klesmith +9 more
semanticscholar +3 more sources
Cancers, 2021 CAR-T cell therapy is not without some clinical adverse effects, namely cytokine storms, due to a massive release of cytokines when CAR-T cells multiply in the body.
Shabirul Haque
exaly +2 more sources
Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins
Molecular Pharmaceutics, 2019 CD19-targeted chimeric antigen receptor (CAR) T-cells (CAR19s) show remarkable efficacy in the treatment of relapsed/refractory acute lymphocytic leukemia and Non-Hodgkin’s lymphoma.
Paul D Rennert +2 more
exaly +2 more sources
Dual CAR-T cells targeting CD19 and CD37 are effective in target antigen loss B cell tumor models.
Molecular Cancer Therapeutics, 2023Chimeric antigen receptor T (CAR-T) cells targeting multiple antigens, may reduce the risk of immune escape following the loss of the target antigen and further increase the efficacy of treatment.
Kanae Imai +10 more
semanticscholar +1 more source
Science Translational Medicine, 2021
Trispecific duoCAR-T cells with optimized costimulatory domains effectively kill tumor cells in antigen-heterogeneous and antigen-replete tumor models.
D. Schneider +12 more
semanticscholar +1 more source
Trispecific duoCAR-T cells with optimized costimulatory domains effectively kill tumor cells in antigen-heterogeneous and antigen-replete tumor models.
D. Schneider +12 more
semanticscholar +1 more source
CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy
Leukemia & Lymphoma, 1995The CD19 antigen plays an important role in clinical oncology. In normal cells, it is the most ubiquitously expressed protein in the B lymphocyte lineage. CD19 expression is induced at the point of B lineage commitment during the differentiation of the hematopoietic stem cell, and its expression continues through preB and mature B cell differentiation ...
R H, Scheuermann, E, Racila
openaire +2 more sources
Donor-derived CD19 chimeric antigen receptor T cells
Current Opinion in Hematology, 2015As immunotherapy matures into possible front-line therapy, new approaches are necessary to expand the capacity to treat more patients. Although most technologies for chimeric antigen receptor (CAR) therapies require autologous T cells, 'off the shelf' sources are highly desired.Sources of T cells for modification with CARs include cord blood and either
Nathan, Singh, David M, Barrett
openaire +2 more sources
CD19: Lowering the Threshold for Antigen Receptor Stimulation of B Lymphocytes
Science, 1992Lymphocytes must proliferate and differentiate in response to low concentrations of a vast array of antigens. The requirements of broad specificity and sensitivity conflict because the former is met by low-affinity antigen receptors, which precludes achieving the latter with high-affinity receptors.
R H, Carter, D T, Fearon
openaire +2 more sources
CD19 Fc-Fusion Protein for Detection of Cells Expressing Anti-CD19 Chimeric Antigen Receptors.
Blood, 2010Abstract Abstract 3756 Chimeric Antigen Receptors (CARs) consist of the antigen-recognition portion of a monoclonal antibody fused to an intracellular signaling domain that is capable of activating T cells. CARs are displayed on the surface of transduced cells, performing non-MHC-restricted antigen recognition and ...
Satiro N. De Oliveira +3 more
openaire +1 more source